Literature DB >> 11014538

Prognostic factors in intracranial ependymomas in children.

D Figarella-Branger1, M Civatte, C Bouvier-Labit, J Gouvernet, D Gambarelli, J C Gentet, G Lena, M Choux, J F Pellissier.   

Abstract

OBJECT: The occurrence of intracranial ependymomas in children is relatively infrequent, and their prognostic factors are still controversial, especially regarding histological composition.
METHODS: A retrospective study was conducted of 37 children treated during the last 20 years for intracranial ependymomas at the Hôpital de la Timone. Both univariate and multivariate statistical analyses were performed to assess the prognostic relevance of patient age and sex, extent of tumor removal, location of the tumor (supratentorial compared with infratentorial, median compared with lateral), tumor histological composition, and adjuvant therapies in affecting the 5-year progression-free survival (PFS) rate and overall survival (OS) rate. The following histopathological features, either alone or in combination, were analyzed: endothelial proliferation, necrosis, loss of differentiating structures (present compared with absent), the number of mitotic figures per 10 hpf, and cellularity (number of nuclei/5 hpf). In addition, immunohistochemical detection of Ki-67 antigen was performed and the Ki-67 labeling index (LI) evaluated in all cases. The 5-year OS and PFS rates were 45% and 25%, respectively (median follow up 34 months). Four patients died of disease without remission (median 163 days) and disease in 21 patients relapsed: 18 in situ and three both in situ and distantly. On univariate analysis total surgical resection and median infratentorial location were associated with a better outcome (p < 0.002) for both OS and PFS. Loss of differentiating structures was associated with poor prognosis (p < 0.008) and the combination of necrosis, endothelial proliferation, and mitotic index greater than 5 was also a negative predictive factor for both OS (p < 0.002) and PFS (p = 0.02). The PFS time was shorter in patients younger than 4 years of age and in patients in whom a Ki-67 LI greater than 1 was found (p = 0.03 and 0.006, respectively). Adjuvant radiotherapy and chemotherapy were not relevant to prognosis. Moreover, among the 15 patients in whom total excision was achieved, OS was better in those who did not receive adjuvant therapies. In contrast, adjuvant therapies significantly enhanced PFS time in patients in whom tumor excision was incomplete.
CONCLUSIONS: This study and analysis of the literature further highlight that total tumor removal is the treatment of choice for ependymomas in children. Postoperative measurement of residual tumor is required, especially because a subgroup of patients might be treated by surgery alone. Median infratentorial ependymomas have to be distinguished from the lateral type. Appropriate and reproducible histological parameters and Ki-67 LI are of interest as predictors of outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014538     DOI: 10.3171/jns.2000.93.4.0605

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  44 in total

Review 1.  Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis.

Authors:  Klara Kuncova; Ales Janda; Pavel Kasal; Josef Zamecnik
Journal:  Pathol Oncol Res       Date:  2009-03-20       Impact factor: 3.201

Review 2.  Supratentorial pediatric cortical ependymomas: a comprehensive retrospective study.

Authors:  Qiguang Wang; Jian Cheng; Si Zhang; Qiang Li; Xuhui Hui; Yan Ju
Journal:  Neurosurg Rev       Date:  2020-06-30       Impact factor: 3.042

3.  Study of chromosome 9q gain, Notch pathway regulators and Tenascin-C in ependymomas.

Authors:  Rakesh Kumar Gupta; Mehar C Sharma; Vaishali Suri; Aanchal Kakkar; Manmohan Singh; Chitra Sarkar
Journal:  J Neurooncol       Date:  2013-11-01       Impact factor: 4.130

4.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

5.  Epidermal growth factor receptor and caveolin-1 coexpression identifies adult supratentorial ependymomas with rapid unfavorable outcomes.

Authors:  Rebecca Senetta; Clelia Miracco; Salvatore Lanzafame; Luigi Chiusa; Rosario Caltabiano; Antonio Galia; Giulia Stella; Paola Cassoni
Journal:  Neuro Oncol       Date:  2010-11-08       Impact factor: 12.300

Review 6.  Initial management of childhood brain tumors: neurosurgical considerations.

Authors:  Farideh Nejat; Mostafa El Khashab; James T Rutka
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

7.  Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas.

Authors:  Tang-Her Jaing; Huei-Shyong Wang; Pei-Kwei Tsay; Chen-Kan Tseng; Shih-Ming Jung; Kuang-Lin Lin; Tai-Ngar Lui
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

Review 8.  Classification and controversies in pathology of ependymomas.

Authors:  Catherine Godfraind
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

9.  Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Authors:  Matthieu Peyre; Frédéric Commo; Carmela Dantas-Barbosa; Felipe Andreiuolo; Stéphanie Puget; Ludovic Lacroix; Françoise Drusch; Véronique Scott; Pascale Varlet; Audrey Mauguen; Philippe Dessen; Vladimir Lazar; Gilles Vassal; Jacques Grill
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 10.  Survival following treatment for intracranial ependymoma: a review.

Authors:  G Tamburrini; M D'Ercole; B L Pettorini; M Caldarelli; L Massimi; C Di Rocco
Journal:  Childs Nerv Syst       Date:  2009-04-22       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.